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Abstract
Background: Hemodialysis patients have high rates of sudden death, but relationships between serum electrolytes,
the dialysis prescription, and intra-dialytic shifts in fluid and electrolyte with arrhythmia are uncertain.
Methods: We analyzed sixty-six hemodialysis patients who underwent loop recorder implantation with continuous
electrocardiographic monitoring, weekly to bi-weekly testing of pre- and post-dialysis electrolytes, and detailed
capture of dialysis prescription and flow sheet data for 6months. The incidence rate ratio (IRR) of reviewer confirmed
arrhythmias (RCA) during dialysis through 8 h after dialysis and associations with serum chemistries and dialytic
parameters were assessed using adjusted, negative-binomial regression.
Results: Among 66 individuals with a mean age of 56 years, 12,480 events were detected in 64 (97%) patients. RCA
nadired 12–24 h after dialysis and increased during the final 12 h of the inter-dialytic interval through the first 8 h after
dialysis. Higher pre-dialysis serum magnesium concentration was associated with lower incidence rate ratio for arrythmia
(IRR per 1mg/dL increase 0.49, 95% CI; 0.25, 0.94), as was dialysate calcium concentration > 2.5mEq/L vs. 2.5 mEq/L (IRR 0.
52, 95% CI: 0.39, 0.70). Neither intradialytic serum potassium nor weight change were significantly associated with RCA
rate. However, there was effect modification such that arrhythmia rate was maximal with concurrently high intradialytic
volume and potassium removal (Pinteraction = 0.01).
Conclusions: Intra and post-dialytic arrhythmias are common in hemodialysis. Additional studies designed to further
elucidate whether modification of the serum magnesium concentration, dialysate calcium concentration, and the extent
of intradialytic potassium and fluid removal reduces the risk of per-dialytic arrhythmia are warranted.
Trial registration: Clinicaltrials.gov NCT01779856. Prospectively registered on January 22, 2013.
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Background
Patients on dialysis experience a disproportionately high
rate of cardiovascular morbidity and mortality with
3-year mortality of nearly 50%. Multiple studies demon-
strate that cardiovascular disease is the most common
cause of death, and approximately two thirds of the car-
diac deaths are consistently attributed to arrhythmias
[1–4]. This increased incidence of cardiovascular disease,
particularly of sudden death, is not fully explained by
traditional cardiovascular risk factors [5, 6] and appears
to be unique to end stage renal disease.
Interestingly, previous studies have shown a clear rela-
tionship between the dialysis cycle and sudden death,
with both cardiac deaths and sudden deaths most likely
to occur following the long, 3-day inter-dialytic interval
[7, 8]. Observational data, have also demonstrated asso-
ciations between serum electrotype concentrations or
the dialysate electrolyte concentration and the risk of
sudden death [9–12].
These observations suggest current approaches to
thrice-weekly dialysis could potentially induce cardiac ar-
rhythmias. However, previous studies analyzing associa-
tions between dialytic parameters and the occurrence of
arrhythmia have primarily been limited to retrospective
analyses of dialysis organization data with large numbers
of clinical events but without detailed electrocardiographic
tracings, frequent laboratories, or detailed capture of the
dialysis prescription. Conversely, the few studies with elec-
trocardiographic data, were constrained by the limits of
available technology to short-term capture of arrhythmia
data over a maximal observation period of 1–3 dialysis
sessions.
To better understand associations between hemodialysis
and the occurrence of arrhythmia we analyzed data from
the the Monitoring in Dialysis (MiD) study [13], which
used implantable loop recorders (ILR) to continuously
capture cardiac rhythm over 6months in patients receiv-
ing maintenance hemodialysis.
Methods
Study population
The design, objectives, and primary outcomes of the Mon-
itoring in Dialysis (MiD) study have been reported previ-
ously [13, 14]. MiD (NCT01779856) was a prospective,
multi-center study conducted in the US and India be-
tween January 2013 and September 2015 designed to
characterize arrhythmias occurring in three times-weekly
hemodialysis dialysis patients. An implantable cardiac
monitoring device (Medtronic Reveal® XT or LINQ) was
inserted to record heart rate and rhythm. Major inclusion
criteria included the following: a) age ≥ 21 years and b) re-
ceiving in-center hemodialysis 3 times/week or with esti-
mated glomerular filtration < 15mL/min/1.73m2 and
expected to start dialysis within 2months (no pre-dialysis
patients were enrolled). Individuals with permanent pace-
makers or implantable defibrillators and those not ex-
pected to remain on in-center dialysis for at least 6
months due to poor prognosis, expected transplant, or
change in modality were excluded. All patients provided
written informed consent, and institutional review board
or ethics committee approval was obtained at each partici-
pating center. The trial was terminated when the last en-
rolled patient had completed the 6-month primary
observation period.
Study procedures
ILR were downloaded and vital signs, dialysis prescrip-
tion, and dialysis flow-sheet parameters were recorded at
each dialysis session for 6 months. In addition, down-
loads were performed after any dialysis session with a
blood draw for a total of up to 5 downloads each week.
Programming parameters used for automated detection
included the following: a) Fast ventricular tachycardia—
180 beats per minute (BP) for 30/40 beats; b) ventricular
tachycardia—130 BPM for 5 beats; c) bradycardia—40
BPM for 4 beats; d) asystole—duration of 3 s; e) atrial
fibrillation detection on with no minimal duration.
Serum chemistries were tested before and after dialysis
twice weekly for 4 weeks and then weekly through 6
months. ILR tracings that were marked by patients as
symptomatic and those with potential arrhythmias were
reviewed by the study sponsor by at least one trained in-
dividual with experience in cardiac signal interpretation
and adjudication. Those potentially meeting the primary
study endpoint, were subsequently adjudicated by a core
lab.
Definitions
The primary study endpoint of clinically significant
arrythmia (CSA) has been previously reported [14] and
included ventricular tachycardia > 115 beats/minute
(modified by protocol amendment to improve detection
specificity to ≥130 beats per minute) lasting ≥30 s,
bradycardia with rate ≤ 40 beats per minute lasting ≥6 s,
asystole for ≥3 s, and patient-marked (symptomatic)
events where ECG review showed an arrhythmia consid-
ered clinically relevant. We report here, the secondary
endpoint of reviewer confirmed arrhythmia (RCA). RCA
was defined as an ILR identified or patient marked event
in which a manual review of the stored ECG tracing
confirmed the presence of abnormal rhythm RCA in-
cluded outcomes meeting the primary endpoint defin-
ition, atrial fibrillation, supraventricular tachycardia, and
sinus tachycardia with rate exceeding 130 beats per mi-
nute. In addition, ECG-confirmed ventricular tachycar-
dia, asystole, and bradycardia of insufficient rate or
duration to meet the primary endpoint definition were
included. As for the primary endpoint of CSA, the RCA
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endpoint was chosen to define a set of events represent-
ing clinically relevant electrical instability and chrono-
tropic dysfunction likely to share common physiologies
and thus meriting joint analysis. ECG reviewers were
not aware of patients characteristics or dialysis prescrip-
tions. .
Statistical analyses
Baseline demographic, dialysis parameters, and labora-
tory characteristics are presented as mean ± standard
deviation (SD), and median interquartile range (IQR)
for continuous variables and percent (n/N) for cat-
egorical variables. Distributions in baseline character-
istics were analyzed according to quartiles of the
observed number of RCA events during follow-up in
the primary analysis and according the dichotomous
presence or absence of RCA during follow-up in a
secondary analysis. Time averaged serum electrolyte
concentrations or dialysis prescription parameters are
presented as the mean or median of all sessions de-
pending on normality. Characteristics between sub-
jects with and without at least one RCA were
compared using an unpaired t-test or Wilcoxon rank
sum test for continuous variables, and Fisher’s exact
tests for categorical variables. Where 3 or more
groups were assessed ANOVA and Kruskal Wallis
tests were used for continuous variables and Fisher’s
exact test was used for categorical variables.
Negative binomial mixed-effect regression was used to
analyze RCA rate over the dialytic week with division
into 3 intra-dialytic periods and 14 inter-dialytic blocks
of 12 h each. Repeated measures within subjects were
accounted for using a random intercept that included an
offset to indicate the time within each period. We ex-
cluded any off-schedule dialysis sessions as well as week
in which dialysis was performed more or less than 3
times because the primary aim was to assess associations
with the thrice weekly dialysis schedule. We used the
lowest frequency period as the reference period for pair-
wise comparisons.
Given that dialytic parameters are most likely to dir-
ectly induce arrythmia during dialysis or within a few
hours after the conclusion of dialysis (and less likely to
be responsible the further out one gets from dialysis), we
investigated differences between sessions with RCA dur-
ing the interval including dialysis or the 8 h immediately
after dialysis using mixed effect models for continuous
measures, or logistic regression (binary or multinomial)
for categorical measures. The random effect of subject
was included in both models. The interval represented
the peak period of intra/post-dialysis arrythmia and was
therefore the time period during which RCA were most
likely to be biologically influenced by the dialysis
procedure.
Negative binomial mixed effect regression was used to
analyze associations of electrolytes, dialysis prescription, and
intradialytic changes in fluid or electrolyte (flux, the differ-
ence between pre and post dialysis values) with RCA during
the interval beginning with the start of each dialysis session
through 8 h after dialysis. A random intercept was included
to account for within-subjects repeated measures. Multivar-
iable analyses were adjusted for age, sex, race, dialysis vin-
tage, and vascular access and incidence rate ratios (IRR)
were calculated. To avoid over-specification of the models,
electrolyte and dialytic parameters of interest were added
individually to this base model. First order interactions be-
tween volume removal (expressed as intra-dialytic weight
change) and dialysate electrolyte concentration were ana-
lyzed to assess for effect modification by the extent of ultra-
filtration given an extensive literature connecting
ultrafiltration and risk of death [15]. All analyses were com-
pleted using SAS v 9.4 (Cary, NC) with P < 0.05 considered
significant.
Results
Baseline characteristics and RCA
Overall, RCA were observed in 64 (97%) subjects during
following-up (Table 1). Among individuals with ≤10, 11–
49, 50–239 and ≥ 240 RCA events during follow-up, mean
age was 61.1 ± 9.1, 56.3 ± 12.0, 54.1 ± 13.0 and 54.1 ± 13.7
years (P = 0.31). Other characteristics at baseline, such as
race, sex, systolic and diastolic blood pressures, cause of
ESRD, ESRD vintage, history of diabetes, and history of
heart failure also did not differ significantly across quartiles
of observed number of RCA events (P ≥ 0.14 for all com-
parisons). Similarly, there were no significant differences in
baseline characteristics among those with (n = 64) and
without (n = 2) RCA (Additional file 1: Table S1).
Among multiple baseline pre-dialysis laboratory tests ex-
amined, few differed significantly across quartiles of observed
RCA (Table 2). However, use of high flux dialyzer was more
frequent among those with a higher number of RCA (31.3,
56.3, 76.5, and 88.2% among those with ≤10, 11–49, 50–239,
and ≥ 240 RCA, P= 0.004). Dialysate chemistries at baseline
were similar across quartiles of observed RCA, but there was
a non-significant trend towards increased use of higher di-
alysate potassium concentrations among those with more
RCA (P= 0.05). Findings were similar when analyzed accord-
ing to the dichotomous presence or absence of RCA during
follow-up. with exception that the dialysate calcium concen-
tration which was significantly higher (2.5 [IQR: 2.5, 2.5] vs.
1.6 [IQR: 1.6, 1.6], P= 0.04) in those with compared to those
without RCA (Additional file 1: Table S2).
RCA and dialytic parameters over time
Given the high proportion of patients with RCA during
follow-up, we analyzed the difference between sessions with
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and without RCA. There were 4154 sessions without RCA
and 605 sessions with RCA during dialysis or during the 8 h
after dialysis. As shown in Table 3, dialysis sessions without
RCA were characterized by lower ultrafiltration rates (9.9 ±
4.9 vs. 10.1 ± 4.6ml/kg/hour, P= 0.01) and intra-dialytic de-
crease in weight (2.6 ± 1.3 vs. 3.0 ± 1.3 kg P= 0.002) as well
Table 1 Baseline characteristics according to the number of reviewer confirmed arrythmias during follow-up
Characteristics All Subjects (N = 66) Number of RCA During Follow-up P Value
≤10 (N = 16) 11–49 (N = 16) 50–239 (N = 17) ≥240 (N = 17)
Age (years) 56.3 ± 12.2 61.1 ± 9.1 56.3 ± 12.0 54.1 ± 13.0 54.1 ± 13.7 0.31
Female 20/66 (30.3%) 5/16 (31.3%) 5/16 (31.3%) 5/17 (29.4%) 5/17 (29.4%) > 0.99
Race 0.15
Asian 23/66 (34.8%) 9/16 (56.3%) 7/16 (43.8%) 4/17 (23.5%) 3/17 (17.6%)
Black 35/66 (53.0%) 7/16 (43.8%) 8/16 (50.0%) 11/17 (64.7%) 9/17 (52.9%)
Other 1/66 (1.5%) 0/16 (0.0%) 0/16 (0.0%) 0/17 (0.0%) 1/17 (5.9%)
White 7/66 (10.6%) 0/16 (0.0%) 1/16 (6.3%) 2/17 (11.8%) 4/17 (23.5%)
Systolic blood pressure 140.8 ± 23.4 140.9 ± 19.9 145.9 ± 23.9 135.8 ± 23.0 140.9 ± 27.0 0.68
Diastolic blood pressure 80 (70, 84) 76 (59, 80) 80 (71, 81) 80 (64, 85) 84 (74, 90) 0.14
Weight (kg) 81.7 (68.2, 95.2) 78.1 (68.8, 91.0) 84.8 (61.7, 89.5) 80.4 (68.9, 119.0) 83.7 (75.8, 108.2) 0.59
BMI≥ 40 6/66 (9.1%) 1/16 (6.3%) 1/16 (6.3%) 2/17 (11.8%) 2/17 (11.8%) > 0.99
Cause of ESRD
Diabetes 28/66 (42.4%) 11/16 (68.8%) 6/16 (37.5%) 4/17 (23.5%) 7/17 (41.2%) 0.14
Glomerulonephritis 6/66 (9.1%) 0/16 (0.0%) 1/16 (6.3%) 4/17 (23.5%) 1/17 (5.9%)
Hypertension 25/66 (37.9%) 5/16 (31.3%) 6/16 (37.5%) 8/17 (47.1%) 6/17 (35.3%)
Other 10.6% (7/66) 0/16 (0.0%) 3/16 (18.8%) 1/17 (5.9%) 3/17 (17.6%)
ESRD Vintage (years) 2.4 (1.2, 5.3)
(N = 65)
2.2 (1.2, 4.3)
(N = 16)
2.9 (1.5, 5.5)
(N = 15)
2.5 (1.2, 5.7)
(N = 17)
2.5 (0.7, 5.3)
(N = 17)
0.78
Prior kidney transplant 9/66 (13.6%) 2/16 (12.5%) 4/17 (23.5%) 3/17 (17.6%) 2/16 (12.5%) 0.25
Previous peritoneal dialysis 7/66 (10.6%) 1/16 (6.3%) 2/16 (12.5%) 2/17 (11.8%) 2/17 (11.8%) > 0.99
Vascular Access
AV Fistula 45/65 (69.2%) 12/16 (75.0%) 12/16 (75.0%) 11/17 (64.7%) 10/16 (62.5%) 0.87
AV Graft 17/65 (26.2%) 3/16 (18.8%) 3/16 (18.8%) 5/17 (29.4%) 6/16 (37.5%)
Catheter 3/65 (4.6%) 1/16 (6.3%) 1/16 (6.3%) 1/17 (5.9%) 0/16 (0.0%)
Diabetes 42/66 (63.6%) 13/16 (81.3%) 10/16 (62.5%) 8/17 (47.1%) 11/17 (64.7%) 0.25
Hyperlipidemia 40/66 (60.6%) 9/16 (56.3%) 8/16 (50.0%) 11/17 (64.7%) 12/17 (70.6%) 0.66
Hypertension 56/66 (84.8%) 15/16 (93.8%) 13/16 (81.3%) 15/17 (88.2%) 13/17 (76.5%) 0.61
Ischemic heart disease 32/66 (48.5%) 10/16 (62.5%) 8/16 (50.0%) 8/17 (47.1%) 6/17 (35.3%) 0.51
History of MI 6/66 (9.1%) 1/16 (6.3%) 2/16 (12.5%) 1/17 (5.9%) 2/17 (11.8%) 0.95
Congestive heart failure 17/66 (25.8%) 3/16 (18.8%) 3/16 (18.8%) 4/17 (23.5%) 7/17 (41.2%) 0.46
Coronary artery bypass surgery 9/66 (13.6%) 4/16 (25.0%) 3/16 (18.8%) 1/17 (5.9%) 1/17 (5.9%) 0.32
Arrhythmia 21/66 (31.8%) 3/16 (18.8%) 4/16 (25.0%) 7/17 (41.2%) 7/17 (41.2%) 0.42
Smoking 0.45
Current 5/66 (7.6%) 0/16 (0.0%) 1/16 (6.3%) 3/17 (17.6%) 1/17 (5.9%)
Never 46/66 (69.7%) 13/16 (81.3%) 9/16 (56.3%) 11/17 (64.7%) 13/17 (76.5%)
Past 15/66 (22.7%) 3/16 (18.8%) 6/16 (37.5%) 3/17 (17.6%) 3/17 (17.6%)
LVEF 55.0 (55.0, 60.0)
(N = 65)
55.0 (55.0, 60.0)
(N = 15)
57.8 (55.0, 63.5)
(N = 16)
60.0 (55.0, 63.0)
(N = 17)
55.0 (55.0, 60.0)
(N = 17)
0.65
Basline characteristics in individuals with and without reviewer confirmed arrhythmia (RCA) during follow-up. BMI body mass index, ESRD end stage renal disease,
AV arterio-venous, LVEF Left ventricular ejection fraction. Data are mean ± SD, median (IQR), or n/N (%)
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being closer to the target dry weight. There were no signifi-
cant differences in pre-dialysis electrolyte concentrations or
intra-dialytic change in electrolytes in sessions with or with-
out RCA. However, dialysate temperature was lower in ses-
sions without RCA (P < 0.001) and use of dialysate with 2.5
mEq/L of calcium was more common in sessions with
RCA. Similar associations were present for dialysate
temperature but not for indices of fluid accumulation or
ultrafiltration rate when analyzing sessions with reviewer
confirmed bradyarrhythmias (Additional file 1: Table S3).
Differences in dialysate calcium were qualitatively similar
but did not achieve significance. In contrast, both indices of
fluid gain and removal as well dialysate calcium and
temperature were different in sessions without and
with reviewer confirmed tachyarrhythmias (Additional
file 1: Table S4).
Time averaged laboratory and dialysis prescription parame-
ters were analyzed to assess their distribution according to the
number of RCA during follow up. (Additional file 1: Tables S5
& S6). Serum chemistries were notable for lower serum mag-
nesium concentration over time in those with more RCA with
concentrations of 2.6, 2.3, 2.3 and 2.2mg/dL among those with
≤10, 11–49, 50–239, and≥ 240 RCA, P=0.01). Among dialysis
parameters analyzed none were significantly different across
categories of the numbers of observed RCA during follow-up.
There were no other significant differences between serum
chemistries or dialysis prescription parameters among individ-
uals with and without RCA during follow-up.
RCA rate
As reported previously there 12,480 RCA detected in 64
(97%) patients at an overall rate of 33.7 (95% CI: 23.4,
Table 2 Laboratory values and dialysis prescription according to the number of reviewer confirmed arrythmias during follow-up
Characteristics All Subjects (N = 66) Number of RCA During Follow-up P Value
Laboratory Parameters ≤10 (N = 16) 11–49 (N = 16) 50–239 (N = 17) ≥240 (N = 17)
Blood Urea Nitrogen (mg/dL)a 59.7 ± 17.8 63.6 ± 22.5 53.4 ± 17.0 63.6 ± 14.5 59.1 ± 17.6 0.39
Sodium (mEq/L)a 138.0 (135.0, 140.0) 137.0 (132.5, 138.5) 137.0 (136.0, 139.5) 139.0 (135.5, 140.0) 140.0 (135.0, 141.0) 0.41
Potassium (mEq/L)a 4.7 (4.2, 5.4) 5.3 (4.6, 5.9) 4.5 (4.2, 5.1) 4.6 (4.2, 5.1) 4.7 (4.4, 5.4) 0.32
CO2 (mEq/L)a 22.2 ± 3.7 20.5 ± 3.4 22.6 ± 2.4 22.7 ± 3.5 22.5 ± 4.9 0.38
Calcium (mg/dL)a 8.7 ± 0.8 8.5 ± 0.8 8.9 ± 0.7 8.8 ± 0.8 8.6 ± 1.1 0.49
Magnesium (mg/dL)a 2.3 (2.0, 2.7) 2.6 (2.2, 3.1) 2.5 (2.1, 2.8) 2.3 (2.1, 2.7) 2.0 (1.7, 2.3) 0.003
Phosphorous (mg/dL)a 5.1 (4.3, 6.3) 5.4 (4.5, 6.6) 5.1 (4.2, 5.7) 5.5 (4.4, 6.6) 4.9 (4.2, 7.7) 0.84
Hemoglobin (g/dL)b 10.7 (9.9, 11.4) 10.5 (9.8, 10.8) 10.6 (9.3, 11.4) 10.5 (9.8, 11.3) 11.2 (11.1, 11.6) 0.06
Albumin (g/dL)a 4.0 (3.8, 4.2) 3.8 (3.6, 4.1) 4.1 (3.9, 4.2) 4.0 (3.8, 4.2) 3.9 (3.8, 4.2) 0.32
spKt/Va 1.5 (1.2, 1.7) 1.2 (1.1, 1.7) 1.5 (1.2, 1.7) 1.6 (1.4, 1.7) 1.5 (1.4, 1.7) 0.48
Dialysis Parameters
Duration of hemodialysis (hrs) 4.0 (3.5, 4.0) 4.0 (3.5, 4.0) 3.9 (3.5, 4.0) 4.0 (3.5, 4.0) 4.0 (3.5, 4.0) 0.99
Dry weight target (kg) 80.5 (65.0, 94.0) 74.3 (66.3, 90.3) 81.5 (61.0, 88.5) 75.0 (65.0, 115.0) 82.0 (73.4, 107.5) 0.55
Kg Over dry weight target 4.2 (2.7, 5.2) 4.0 (2.5, 5.4) 3.5 (1.8, 4.9) 4.7 (2.8, 5.1) 4.3 (3.1, 5.5) 0.44
Ultrafiltration rate (ml/kg/hr) 10.9 (7.4, 15.9) 11.4 (7.7, 13.2) 10.7 (6.3, 16.0) 10.9 (7.5, 15.9) 11.0 (9.2, 15.9) 0.84
Sodium modeling 9/66 (13.6%) 4/16 (25.0%) 2/16 (12.5%) 1/17 (5.9%) 2/17 (11.8%) 0.47
High flux dialyzer 42/66 (63.6%) 5/16 (31.3%) 9/16 (56.3%) 13/17 (76.5%) 15/17 (88.2%) 0.004
Membrane reuse 18/66 (27.3%) 4/16 (25.0%) 3/16 (18.8%) 4/17 (23.5%) 7/17 (41.2%) 0.55
Cellulose membrane 5/66 (7.6%) 3/16 (18.8%) 2/16 (12.5%) 0/17 (0.0%) 0/17 (0.0%) 0.06
Dialysate temperature (°C) 37.0 (37.0, 37.0) 37.0 (36.8, 37.0) 37.0 (37.0, 37.0) 37.0 (37.0, 37.0) 37.0 (37.0, 37.0) 0.52
Dialysate sodium (mEq/L)c 140.0 (140.0, 140.0) 140.0 (138.0, 140.0) 140.0 (140.0, 140.0) 140.0 (140.0, 140.0) 140.0 (140.0, 140.0) 0.30
Dialysate potassium (mEq/L)d 2.0 (2.0, 2.0) 2.0 (2.0, 2.0) 2.0 (2.0, 2.0) 2.0 (2.0, 2.0) 2.0 (2.0, 3.0) 0.05
Dialysate bicarbonate (mEq/L) 35.0 (33.0, 36.0) 35.0 (32.5, 35.0) 35.0 (32.0, 36.0) 35.0 (35.0, 37.0) 35.0 (35.0, 40.0) 0.33
Dialysate calcium (mEq/L) 2.5 (2.5, 2.5) 2.5 (1.6, 2.5) 2.5 (2.1, 3.0) 2.5 (2.5, 2.5) 2.5 (2.5, 2.5) 0.44
Distribution of baseline lab tests and dialysis parameters. Continuous variables are presented as mean ± standard deviation or median (interquartile range). CO2-
total carbon dioxide (bicarbonate)
SpKt/V single pool Kt/V according to Daugirdas formula, CRP HS-high sensitivity CRP, PTH parathyroid hormone, Hrs hours, mEq milliequivalent, mg milligram, dL
deciliter, L liter, pg picogram, Celsius, mL milliliter, Kg kilogram, CRP, PTH and BNP were measured in US patients only
a Available in 59 patients (≤10 RCA (n = 12), 11–49 RCA (n = 16), 50–240 RCA (n = 16) > 240 RCA (n = 15). bAvailable in 56 patients (≤10 RCA (n = 12), 11–49 RCA
(n = 14), 50–240 RCA (n = 17) > 240 RCA (n = 13). c Dialysate sodium was available in 61 patients overall (≤10 RCA (n = 14), 11–49 RCA (n = 14), 50–240 RCA (n = 17)
> 240 RCA (n = 16). d Mean values for potassium in mEq/L = 1.9 ± 0.3, 2.3 ± 0.6, 2.2 ± 0.4, and 2.4 ± 0.5
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Table 3 Characteristics of sessions with and without RCA during follow-up
Characteristic Sessions without RCA Session with RCA P
ValueNumber of Sessions Mean ± SD or Median
(IQR)
Number of Sessions Mean ± SD or Median
(IQR)
Duration of hemodialysis (hrs) 4154 3.8 ± 0.5 605 3.9 ± 0.6 0.80
Dry weight (kg) 4150 84.8 ± 27.9 605 90.1 ± 30.2 0.83
Percent over dry weight (%) 4138 3.9 ± 2.4 604 3.9 ± 2.4 0.04
Kilogram over dry weight 4138 3.1 ± 1.9 604 3.6 ± 2.1 0.07
Ultrafiltration rate (ml/kg/hr) 4154 9.9 ± 4.9 605 10.1 ± 4.6 0.01
Intradialytic decrease in weight (kg) 4138 2.6 ± 1.3 604 3.0 ± 1.3 0.002
Pre-dialysis potassium (mEq/L) 1408 4.9 ± 0.8 259 5.0 ± 0.8 0.74
Intradialytic potassium change (mEq/L) 1364 −1.2 ± 0.8 253 − 1.3 ± 0.8 0.13
Pre-dialysis calcium (mEq/L) 1416 8.7 ± 0.9 260 8.8 ± 0.8 0.56
Intra-dialytic calcium change (mEq/L) 1366 0.7 ± 1.1 254 0.6 ± 0.9 0.53
Pre-dialysis magnesium (mg/dL) 1416 2.4 ± 0.5 260 2.2 ± 0.4 0.88
Intradialytic magnesium change (mg/dL) 1370 −0.3 ± 0.3 255 0.3 ± 0.3 0.97
Pre-dialysis phosphorus (mg/dL) 1414 5.3 ± 1.7 260 5.1 ± 1.7 0.31
Intradialytic phosphorus change (mg/dL) 1362 −3.0 ± 1.5 255 −3.0 ± 1.5 0.28
Pre-dialysis bicarbonate (mEq/L) 1415 22.1 ± 3.9 260 22.7 ± 4.2 0.87
Intradialytic bicarbonate change (mEq/L) 1368 4.9 ± 3.3 255 4.5 ± 3.5 0.75
Pre-dialysis sodium (mEq/L) 1416 136.6 ± 4.3 260 137.9 ± 4.1 0.16
Intradialytic sodium change (mEq/L) 1366 0.6 ± 4.1 254 0.0 ± 3.4 0.28
Nadir intradialytic systolic blood pressure
(mm Hg)
4148 120.0 (105.0, 138.0) 605 113.0 (99.0, 130.0) 0.31
Nadir intradialytic diastolic blood pressure
(mm Hg)
4148 67.0 (56.0, 74.0) 605 62.0 (54.0, 71.0) 0.06
Dialysis Prescription Parameters Number of Sessions
(n/N)
% Number of Sessions
(n/N)
%
Dialysate temperature <
0.001
36–36.9 °C 541/4064 13.3% 46/596 7.7%
≥37 °C 3523/4064 86.7% 550/596 92.3%
Dialysate potassium 0.26
2.0 mEq/L 3327/4008 83.0% 422/595 70.9%
3.0 mEq/L 681/4008 17.0% 173/595 29.1%
Dialysate calcium <
0.001
< 2.0 mEq/L 925/4146 22.3% 31/604 5.1%
2.0–2.4 mEq/L 81/4146 2.0% 1/604 5.1%
2.5 mEq/L 2211/4146 53.3% 433/604 71.7%
> 2.5 mEq/L 929/4146 22.4% 139/604 23.0%
Dialysate sodium 0.67
≤ 135mEq/L 501/3803 13.2% 70/558 12.5%
136–139mEq/L 408/3803 10.7% 21/558 3.8%
140mEq/L 2894/3803 76.1% 467/558 83.7%
Sodium modeling 581/4140 14.0% 48/603 8.0% 0.40
Dialysate bicarbonate 0.20
≤ 28mEq/L 215/4043 5.3% 29/600 4.8%
29–34mEq/L 962/4043 23.8% 125/600 20.8%
35mEq/L 1548/4043 38.3% 217/600 36.2%
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48.7) per patient/month. Multiple episodes demonstrated
more than a single type of arrythmia on the tracing, and the
total included 7488 atrial arrythmias, 913 ventricular arryth-
mias, 1770 bradycardia events, 31 asystole, and 6065 sinus
tachycardias. The atrial arrythmias included 4419 atrial fibril-
lation events [16]. There were clear temporal patterns with a
nadir occurring 12–24 h after dialysis and an increase in rate
during the last 12 h of the inter-dialytic interval through 12 h
after dialysis (Fig. 1a). Additional, post-hoc exploration dem-
onstrated that the majority of post-dialysis RCA occur within
8 h after dialysis, and that RCA rate during the next 4 h is
not significantly different from that during the nadir period
at 12–24 h after 3rd weekly session (Fig. 1b).
Given this distribution and noting that biologically dia-
lytic parameters are most likely to directly induce arryth-
mia during dialysis or within a few hours after the
conclusion of dialysis (and less likely to be responsible
the further out one gets from dialysis), we hypothesized
the effects of pre-dialysis electrolytes, the dialysis pre-
scription, and the dialysis procedure would be most ap-
parent during dialysis or the 8 h immediately (the period
with maximal arrythmia incidence rate). Crude and ad-
justed associations with RCA rate during dialysis and
the 8 h immediately afterwards are shown in Table 4.
Only 4 parameters were associated with RCA rate in
adjusted analyses: Higher pre-dialysis magnesium
Table 3 Characteristics of sessions with and without RCA during follow-up (Continued)
Characteristic Sessions without RCA Session with RCA P
ValueNumber of Sessions Mean ± SD or Median
(IQR)
Number of Sessions Mean ± SD or Median
(IQR)
> 35 mEq/L (1318/4043) 32.6% 229/600 38.2%
Data are presented as number of sessions over mean ± standard deviation or as % (n/N)>. Hrs hours, Kg kilogram, mL milliliter, mg/dL milligram per deciliter, mm
Hg millimeters of mercury
Fig. 1 Rate of reviewer confirmed arrhythmia during and between dialysis sessions-- Reviewer confirmed arrhythmia rate over the course of the
dialytic week. a RCA during the intradialytic interval or successive 12-h intervals from 1 session until the next dialysis session. HD1–3 Intra-1st, 2nd
or 3rd, intradialytic interval of the week. b RCA during the intradialytic interval through 8 h after dialysis, 8–12 h after dialysis, or successive 12-h
intervals until the next dialysis session. HD1–8, HD2–8, HD3–8—1st, 2nd or 3rd, intradialytic interval of the week through 8 h post dialysis. Blue, red,
green-1st 2nd or 3rd dialysis session and subsequent inter-dialytic interval of the week. * signifies P < 0.05 compared to nadir rate for the week
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concentrations were associated with lower risks of RCA
(IRR 0.49, 95% CI: 0.25, 0.94). Conversely, dialysate cal-
cium concentrations below 2.0 mEq/L (IRR 0.13, 95% CI:
0.03, 0.57) and above 2.5 mEq/L were associated with
lower risks of RCA compared to 2.5 mEq/L dialysate
(IRR 0.52, 95% CI: 0.39, 0.70). Dialysate sodium concen-
trations of 135–139mEq/L were also associated with a
reduced rate compared to dialysate sodium of 140 mEq/
L (IRR 0.40, 95% CI: 0.17, 0.95) as were dialysate bicar-
bonate concentrations > 35 mEq/L compared to concen-
trations of 35 mEq/L (IRR 0.51, 95% CI: 0.27, 0.97).
Other factors were not significantly associated with RCA
rate. Lastly, there was evidence for significant interaction
between intradialytic change in potassium and change in
weight (Pinteraction = 0.01)—whereas RCA rate changed
minimally with potassium flux when ≤2 kg were re-
moved, there were sharp increases in RCA rate with
greater potassium flux with ≥3 kg of ultrafiltration
(Fig. 2).
Results were qualitatively similar for reviewer con-
firmed bradyarrhythmias and tachyarrhythmias when
they were analyzed separately with 3 exceptions: Higher
Table 4 Associations of electrolytes and dialysis parameters with RCA rate from the beginning of each dialysis session to 8-h post-
dialysis
Parameter Crude IRR (95% CI) P Value Adjusted IRR (95% CI) P Value
Electrolyte Concentration
Pre-dialysis potassium 1.26 (0.96, 1.65) 0.10 1.28 (0.97, 1.69) 0.08
Intradialytic potassium change 0.78 (0.60, 1.01) 0.06 0.78 (0.60, 1.01) 0.06
Pre-dialysis calcium 0.92 (0.65, 1.31) 0.65 0.80 (0.56, 1.15) 0.23
Intra-dialytic calcium change 1.06 (0.83, 1.34) 0.65 1.16 (0.90, 1.49) 0.26
Pre-dialysis magnesium 0.41 (0.21, 0.78) 0.01 0.49 (0.25, 0.94) 0.03
Intradialytic magnesium change 1.29 (0.57, 2.94) 0.54 1.56 (0.64, 3.78) 0.33
Pre-dialysis phosphorus 1.06 (0.89, 1.26) 0.53 1.00 (0.84, 1.19) 0.96
Intradialytic phosphorus change 0.95 (0.80, 1.14) 0.58 1.02 (0.84, 1.23) 0.86
Pre-dialysis bicarbonate 1.01 (0.95, 1.07) 0.78 0.97 (0.93, 1.03) 0.28
Intradialytic bicarbonate change 0.98 (0.92, 1.05) 0.62 0.99 (0.93, 1.06) 0.80
Sodium pre-dialysis 1.07 (0.99, 1.15) 0.08 1.04 (0.97, 1.11) 0.25
Intradialytic sodium change 0.97 (0.92, 1.03) 0.34 0.98 (0.93, 1.04) 0.54
Dialysis Prescription Parameters
Dialysate temperature≥ 37 vs. 36–36.9 °C 3.87 (0.95, 15.78) 0.06 4.30 (0.97, 19.17) 0.06
Dialysis potassium 3 vs. 2 mEq/L 1.23 (0.63, 2.61) 0.49 1.12 (0.59, 2.13) 0.73
Dialysate calcium
< 2 vs. 2.5 mEq/L 0.11 (0.04, 0.31) < 0.001 0.13 (0.03, 0.57) 0.01
2.0–2.4 vs. 2.5 mEq/L 0.11 (0.00, 7.30) 0.30 0.09 (0.00, 10.50) 0.32
> 2.5 vs. 2.5 mEq/L 0.54 (0.36, 0.83) 0.004 0.52 (0.39, 0.70) < 0.001
Dialysate Sodium
≤ 135 vs. 140 mEq/L 2.31 (0.59, 9.01) 0.23 2.31 (0.60, 8.93) 0.23
135–139 vs. 140 mEq/L 0.38 (0.12, 1.21) 0.10 0.40 (0.17, 0.95) 0.04
Sodium modelling (vs. fixed sodium) 0.57 (0.21, 1.58) 0.28 0.77 (0.37, 1.59) 0.47
Dialysate bicarbonate
≤ 28 vs. 35 mEq/L 0.25 (0.04, 1.69) 0.15 0.39 (0.07, 2.34) 0.31
> 28–34 vs. 35 mEq/L 0.43 (0.18, 1.06) 0.07 0.96 (0.30, 3.07) 0.95
> 35 vs. 35 mEq/L 0.74 (0.36, 1.52) 0.41 0.51 (0.27, 0.97) 0.04
Intradialytic weight change (per Kilogram) 1.16 (1.02, 1.31) 0.02 1.10 (0.99, 1.22) 0.08
Nadir SBP 1.00 (0.99, 1.01) 0.93 0.99 (0.98, 1.00) 0.21
Nadir DBP 1.01 (0.99, 1.02) 0.35 1.00 (0.98, 1.02) 0.98
Crude and adjusted associations with RCA rate from the start of one dialysis to 8 h after post dialysis. Adjusted models include age, sex, race, vascular access type,
and dialysis vintage. All sessions are included. Kg-kilogram. mL-milliliter. mEq/L-milliequivalent/liter. Pre- and intradialytic potassium, calcium, bicarbonate and
sodium per 1 mEq/L increase in electrolyte. Pre and intradialytic magnesium and phosphorous per 1 mg/dL change
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pre-dialysis phosphorous was associated with lower rates
of tachyarrhythmia (IRR 0.45, 95% CI: 0.23, 0.91), higher
pre-dialysis bicarbonate was associated with lower rates
of bradycardia (IRR 0.73, 95% CI: 0.55, 0.98), and brady-
cardia was less frequent with large intradialytic weight
change (IRR 0.58, 95% CI: 0.40, 0.83).
Discussion
We studied 66 hemodialysis patients with implantable
loop recorders to characterize arrhythmias and their re-
lationship to the dialysis procedure during a prolonged
monitoring period. We found that 97% of patients expe-
rienced an EKG-verified arrhythmia during follow-up.
RCA were detected at a rate exceeding 1 event per
patient-day of follow-up, and they were most frequent
during and shortly after dialysis as well during the last
hours of the inter-dialytic window. Although arrhyth-
mias were frequent and clearly tracked the dialytic cycle,
among modifiable factors several related to the dialysis
prescription including pre-dialysis magnesium, the di-
alysate calcium concentration, sodium, and bicarbonate
concentrations and the combination of high levels of
ultrafiltration and potassium flux during dialysis were
significantly associated with RCA rate.
Sudden cardiac death is the single most important cause
of mortality in hemodialysis patients and is responsible for
almost a third of mortality. While it’s clear that the tem-
poral profile of sudden death mirrors the dialysis cycle
with a preponderance of events related to the long
inter-dialytic period [7], our overall knowledge base re-
mains incomplete with regards to the specific role of the
dialysis procedure (with its significant fluid and electrolyte
fluxes) in the pathogenesis of this condition. The current
analysis of the Monitoring in Dialysis (MiD) study pro-
vides important ancillary information demonstrating
increased risks for arrhythmia during the peri-dialytic
period and identifies several modifiable factors that may
represent targets for interventional studies seeking to
lower the risk of arrhythmia and sudden death in
hemodialysis patients.
Several retrospective cohort studies have demonstrated
that the risk of cardiovascular death, cardiovascular hos-
pitalizations and sudden death increase following the
long interdialytic interval [7, 8]. These data suggest that
increases in the incidence of sudden death in dialysis pa-
tients are not solely the result of uremia-induced
changes in the myocardium, but instead reflect the abil-
ity of the aphysiologic nature of intermittent
hemodialysis to trigger the spread of arrhythmias in this
vulnerable substrate. More recently, several studies have
implicated the dialysis prescription—specifically the use
of high ultrafiltration rates or dialysates with low con-
centrations of potassium or calcium [9, 10, 15, 17].
Nevertheless the underlying arrhythmias responsible for
sudden death or indeed whether the majority of sudden
deaths are attributable to fatal arrhythmia versus myocardial
infarction or non-cardiac causes remains uncertain [18]. Al-
though these studies provide compelling evidence linking
the dialysis prescription to sudden death, a major drawback
to each is the absence of electrocardiographic data demon-
strating the presence of an underlying arrhythmia in cases
of sudden death or an increase in arrhythmias in response
to changes in these dialysis parameters. Several more recent
studies have used implantable loop monitoring technology
to confirm that arrhythmias are common in hemodialysis
patients and occur in a pattern mimicking the observed pat-
terns of sudden death in registry-based analyses [14, 19, 20],
and in the study by Buitten, atrial fibrillation was more
common following sessions with lower dialysate potassium
concentrations or higher ultrafiltration volumes.
Fig. 2 Incidence rate of reviewer confirmed arrhythmias according to intradialytic change in potassium and weight—Rate of reviewer confirmed
arrhythmias per hour according to intra-dialytic change in potassium and the pre-post dialysis decrease in weight from the start of dialysis to 8 h
post. The interaction term for intradialytic change in weight*intradialytic change in potassium was estimated as an IRR of 0.78 (95% CI: 0.66, 0.93)
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Our analysis extends upon these finding in several
ways. We recorded detailed information about the dialy-
sis prescription, blood pressure, and ultrafiltration at
every session for 6 months, and we tested blood chemis-
tries using a central lab both before and after dialysis at
least weekly for 6 months and bi-weekly during the first
month after ILR insertion. To our knowledge, the previ-
ous investigations using long-term monitoring during
dialysis only recorded the clinical laboratory data (gener-
ally drawn once per month), recorded dialysis parame-
ters on only a subset of dialysis sessions, and had no
information on post-dialysis electrolyte concentrations.
Thus, our findings are based on much richer and more
detailed data on the dialysis prescription, peri-dialytic
parameters (such as fluid removed), and serum electro-
lytes. Furthermore, to our knowledge, the current study
is unique in having with the data needed to assess the
impact of electrolyte flux on arrhythmia.
Although we did not identify a significant association
between dialysate potassium or fluid removed and the
incidence of arrhythmia, we did find a significant inter-
action demonstrating that arrhythmia rate increased as
the amount of volume removed and the change in po-
tassium during dialysis increased. It should be noted that
use of 1 mEq/L potassium dialysate was infrequent in
our population, and it is therefore possible that we
lacked sufficient power to detect an association between
low potassium dialysate and arrhythmia rate.
We also identified a protective effect with the use of
high concentration calcium dialysate which is fully con-
sistent with registry-based studies suggesting an increase
in sudden death risk with the use of low calcium dialys-
ate [10]. The protective effect of low calcium dialysates
we observed is harder to explain, but it could reflect use
of lower calcium dialysates in individuals with significant
hypercalcemia or hyperphosphatemia. Our finding that
higher serum magnesium concentration is associated
with a reduced rate of arrhythmia during and after dialy-
sis is unique, but consistent with several recent registry
analyses suggesting that the risk of all-cause, cardiovas-
cular and sudden death is increased in hemodialysis pa-
tients with lower magnesium levels [21–23]. Given poor
excretion of magnesium in end stage renal disease and
the fixed nature of magnesium in standard dialysate
baths, interest in the role of magnesium as a risk factor
has been less than for other serum electrolytes. Our data
suggests that further investigation of its role and consid-
eration of studies manipulating the magnesium concen-
tration in the dialysate or of oral supplementation
should be considered. Unfortunately, dialysate magne-
sium concentration was not recorded in MiD and we
could not directly assess this parameter.
Finally, we observed a decrease in arrhythmia rate with
the use of dialysate sodium concentrations of 135–139
mEq/L (compared with 140 mEq/L) and bicarbonate
concentrations > 35 mEq/L (compared with 35mEq/L).
The observed associations are intriguing given prior data
implicating high dialysate sodium concentrations and
acidosis as risk factors for mortality on dialysis [24–27].
Although our findings provide new insights into the
pathogenesis of arrhythmia in hemodialysis patients,
they differ from prior analyses identifying 1mEq/L po-
tassium and low calcium concentration dialysates as risk
factors for sudden death [9, 10, 28]. Differences in the
timing of the events captured (during dialysis to 8 h post
vs. intradialytic only, or any time during follow-up), the
number of patients exposed to low dialysate electrolyte
concentrations, and the nature of the captured events
(EKG-confirmed arrythmia vs. non-adjudicated sudden
deaths that may have included deaths due to stroke,
myocardial infarction, pulmonary embolism or vascular
accidents) may account for the differential findings.
Nevertheless, the differential findings suggest cautious
interpretation and generalization of our data.
Several additional limitations should be kept in mind.
First, we studied repeated prescription changes within a
selected population of 66 patients that did not include
any Hispanics rather than a larger more ethnically di-
verse population. Additionally, most individuals in MiD
had been on dialysis longer than 1 year. The population
studied is thus likely to over-represent survivors of the
first year of dialysis during which the risk of sudden
death is highest. Our findings should be generalized cau-
tiously, particularly to incident patients. The sample size
was small and extreme dialysate prescriptions (such as
use of 1 mEq/L potassium dialysate) or electrolyte ab-
normalities were infrequent. These factors may have lim-
ited our power to detect associations with arrhythmia
risk. In addition, we investigated multiple risk factors
without correcting for multiple comparisons. Although
correction for multiple comparisons, would have low-
ered the risk of type 2 error, it would have increased the
risk of missing potentially important associations merit-
ing further exploration. In light of the unique nature of
our data and exploratory nature of our analysis, we
chose not to utilize a correction procedure, and our
findings should be considered hypothesis forming rather
than definitive.
Our primary analysis examined all reviewer confirmed
arrythmias. Power for the individual, post-hoc analyses
of brady and tachyarrhythmias was more limited. How-
ever, results, were generally consistent with the primary
analysis although larger intradialytic weight changes
tended to decrease the likelihood of bradycardia as
would be expected with volume depletion. Dedicated
studies to better define the risk factors for individual
arrythmia types are warranted. Finally, it should be
noted that although the period starting with dialysis
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through eight hours post-dialysis was rationally selected
as the most likely period to provide an informative ana-
lysis, this interval was selected following investigation of
the periodicity of the underlying arrythmia rates.
Whether alternative intervals would better represent the
period in which heart rhythm is most likely to be dir-
ectly and immediately influenced by the dialysis
procedure.
In summary, we evaluated the occurrence of arrhythmia
in hemodialysis patients during 6 months of intensive data
capture and continuous electrocardiographic monitoring
using implantable loop recorders with reviewer confirm-
ation of identified arrhythmias. Arrhythmias were common,
occurred in a temporal pattern related to thrice-weekly dia-
lysis intervals, and were associated with potentially modifi-
able parameters such as serum magnesium, dialysate
calcium and fluid and potassium flux during dialysis. Large
studies to further develop these insights are needed, but
our findings confirm the promise of individualizing the dia-
lysis prescription as potentially important method of min-
imizing cardiac arrhythmias and sudden death in dialysis
patients.
Conclusions
In conclusion, peri-dialytic arrythmias are common in
hemodialysis patients. They peak during the final 12 h of
the inter-dialytic interval through the first 8 h after dialy-
sis and may be more likely with use of low magnesium
dialysate or jointly high rates of intra-dialytic potassium
and fluid removal. Strengths of our analysis include the
detailed capture of data and the continuous collection of
heart rate data over 6 months. Limitations include the
small sample size and infrequent occurrence of extreme
electrolyte abnormalities or dialysate concentrations.
Additional studies to validate and generalize our findings
are warranted.
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